

10667182

=> d his

(FILE 'HOME' ENTERED AT 15:43:38 ON 25 JUN 2004)

FILE 'REGISTRY' ENTERED AT 15:43:52 ON 25 JUN 2004
L1 STRUCTURE UPLOADED
L2 3 S L1
L3 56 S L1 SSS FULL


FILE 'CAPLUS' ENTERED AT 15:44:38 ON 25 JUN 2004
L4 3 S L3

FILE 'BEILSTEIN' ENTERED AT 15:45:48 ON 25 JUN 2004
L5 0 S L1
L6 0 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 15:46:12 ON 25 JUN 2004
L7 0 S L3
L8 3 S L3 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:46:49 ON 25 JUN 2004
L9 3 S L8
L10 0 S L9 NOT L4

=> d 11
L1 HAS NO ANSWERS
L1 STR




10667182


=> d 1-3 bib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:267332 CAPLUS
DN 140:303670
TI Preparation of imidazopyridines as 5-HT4 receptor agonists
IN Iguchi, Satoru; Katsu, Yasuhiro; Kon-I, Kana; Noguchi, Hirohide; Uchida, Chikara
PA Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004026869	A1	20040401	WO 2003-IB3971	20030908
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004122043	A1	20040624	US 2003-667188	20030917
PRAI US 2002-412485P	P	20020920		
OS MARPAT	140:303670			
GI				



AB The title compds. [I; R1 = H, halo; R2 = Me, Et; R3 = branched alkyl or alkyl substituted by alkoxy; with the proviso that when the terminal carbon atom of said alkyl group is substituted by said alkoxy group, said alkyl group is a branched alkyl group] which have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans, were prepared. E.g., a 6-step synthesis of I [R1 = Cl; R2 = Me; R3 = iso-Bu] which showed Ki of 0.82 nM against 5-HT4 binding, was given. This invention also provides a pharmaceutical composition comprising the compound I.
IT 519148-48-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of imidazopyridinecarboxamides as 5-HT4 receptor agonists)
RN 519148-48-2 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[(1-(2-methylpropyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




IT 519148-50-6P 519148-51-7P 519148-52-8P
 519148-53-9P 676322-47-7P 676322-48-8P
 676322-49-9P 676322-50-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of imidazopyridinecarboxamides as 5-HT4 receptor agonists)
 RN 519148-50-6 CAPLUS
 CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-2-methyl-N-[(1-(2-methylpropyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 519148-51-7 CAPLUS
 CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[(1-(3,3-dimethylbutyl)-4-piperidinyl)methyl]-2-ethyl- (9CI) (CA INDEX NAME)

10667182



RN 519148-52-8 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[(1-(2-methoxy-2-methylpropyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 519148-53-9 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[(1-(2-methoxy-2-methylpropyl)-4-piperidinyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)


10667182



RN 676322-47-7 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[(1-(2,2-dimethylpropyl)-4-piperidinyl)methyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 676322-48-8 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[(1-(2,2-dimethylpropyl)-4-piperidinyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



10667182


RN 676322-49-9 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3-methoxy-3-methylbutyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 676322-50-2 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3-methoxy-2,2-dimethylpropyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)




IT 519147-99-0P 676322-53-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyridinecarboxamides as 5-HT4 receptor agonists)

RN 519147-99-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[[(5-amino-6-chloro-2-ethylimidazo[1,2-a]pyridin-8-yl)carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10667182



RN 676322-53-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(5-amino-6-chloro-2-methylimidazo[1,2-a]pyridin-8-yl)carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:267331 CAPLUS
DN 140:303669
TI Preparation of N-(piperidin-4-ylmethyl) imidazopyridinecarboxamides as 5-HT4 receptor modulators
IN Katsu, Yasuhiro; Kon-I, Kana; Morita, Mikio; Noguchi, Hirohide; Uchida, Chikara
PA Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.
SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004026868	A1	20040401	WO 2003-IB3945	20030908


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-412426P P 20020920

OS MARPAT 140:303669

GI




AB The title compds. [I; R1 = H, halo; R2 = H, alkyl, aminocarbonyl, mono- or dialkylaminocarbonyl; R3 = alkyl which is substituted by at least one substituent selected from the group consisting of substituents α ; said substituents α = aryl, OH, oxo, heterocyclyl, etc.] which have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastrosophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans, were prepared. E.g., a multi-step synthesis of I [R1 = Cl; R2 = H; R3 = 3,3-dimethyl-2-oxobutyl], starting from Et 6-[(2,2,-dimethylpropanoyl)amino]-2-fluoronicotinate, was given. All compds. I prepared in the working examples showed Ki of 0.19 nM to 47 nM with respect to the affinity to the 5-HT4 receptor. This invention also provides a pharmaceutical composition comprising the compound I.

IT **676351-57-8P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of N-(piperidin-4-ylmethyl) imidazopyridinecarboxamides as 5-HT4 receptor modulators)

RN 676351-57-8 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[(1-(3,3-dimethyl-2-oxobutyl)-4-piperidinyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



IT **676351-56-7P 676351-58-9P 676351-59-0P**
676351-60-3P 676351-61-4P 676351-62-5P


10667182

676351-63-6P 676351-64-7P 676351-65-8P
676351-66-9P 676351-67-0P 676351-68-1P
676351-69-2P 676351-70-5P 676351-71-6P
676351-72-7P 676351-73-8P 676351-74-9P
676351-75-0P 676351-76-1P 676351-77-2P
676351-78-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(piperidin-4-ylmethyl) imidazopyridinecarboxamides as 5-HT4 receptor modulators)


RN 676351-56-7 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[(1-(3,3-dimethyl-2-oxobutyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 676351-58-9 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-(3,3-dimethyl-2-oxobutyl)-4-piperidinyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 676351-59-0 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[(1-(3,3-dimethyl-2-oxobutyl)-4-piperidinyl)methyl]-2-ethyl- (9CI) (CA INDEX NAME)

10667182




RN 676351-60-3 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[(1-(3-hydroxy-3-methyl-2-oxobutyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 676351-61-4 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[(1-(4-hydroxy-3,3-dimethyl-2-oxobutyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 676351-62-5 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[(1-[2-oxo-2-(1-piperidinyl)ethyl]-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 676351-63-6 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[(1-[2-(4-morpholinyl)-2-oxoethyl]-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 676351-64-7 CAPLUS



CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[(1-[3-(4-morpholinyl)-3-oxopropyl]-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)





RN 676351-65-8 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[(1-[2-[(4-(1,1-dimethylethyl)phenyl)ethyl]-4-piperidinyl)methyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 676351-66-9 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[(1-[2-[(methylsulfonyl)amino]ethyl]-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

10667182



RN 676351-67-0 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[(1-(2-hydroxy-3,3-dimethylbutyl)-4-piperidinyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 676351-68-1 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[(1-(2-hydroxybutyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

10667182




RN 676351-69-2 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[(1-(2-hydroxybutyl)-4-piperidinyl)methyl]-, ethanedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 676351-68-1


CMF C20 H30 Cl N5 O2



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 676351-70-5 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[(1-(2-hydroxy-2-methylpropyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

10667182



RN 676351-71-6 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[(1-(2-hydroxy-2-methylpropyl)-4-piperidinyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 676351-72-7 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[(1-[(2R)-3-hydroxy-2-methylpropyl]-4-piperidinyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10667182

RN 676351-73-8 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[(1-(1,3,3-trimethyl-2-oxobutyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 676351-74-9 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[(1-[2-(1-methylcyclopropyl)-2-oxoethyl]-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 676351-75-0 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[(1-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 676351-76-1 CAPLUS
 CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[(1-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-4-piperidinyl)methyl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A






RN 676351-77-2 CAPLUS
 CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[(1-(2-hydroxy-1,1-dimethylethyl)-4-piperidinyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 676351-78-3 CAPLUS
 CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[(1-(tetrahydro-2H-pyran-4-yl)methyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




10667182

IT 519147-99-0P 676322-53-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(piperidin-4-ylmethyl) imidazopyridinecarboxamides as 5-HT4 receptor modulators)


RN 519147-99-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(5-amino-6-chloro-2-ethylimidazo[1,2-a]pyridin-8-yl)carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 676322-53-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(5-amino-6-chloro-2-methylimidazo[1,2-a]pyridin-8-yl)carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:335105 CAPLUS

DN 138:353992

TI Preparation of imidazopyridines as 5-HT4 receptor modulators

IN Fenwick, David Roy; Gymer, Geoffrey Edward; Noguchi, Hirohide; Stobie, Alan; Uchida, Chikara

PA Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.

SO PCT Int. Appl., 82 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035649	A1	20030501	WO 2002-IB4098	20021003
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003092699	A1	20030515	US 2002-251109	20020920
	US 6624162	B2	20030923		
	US 2004034226	A1	20040219	US 2003-617920	20030710
PRAI	US 2001-343371P	P	20011022		
	US 2002-412485P	P	20020920		
	US 2002-251109	A3	20020920		
OS	MARPAT 138:353992				
	GI				



AB Title compds. [I; R1 = H, halo, alkyl; R2, R3 = H, alkyl, alkenyl, alkynyl, aminoalkyl, hydroxyalkyl; R2R3N = (substituted) heterocyclyl; R4 = H, halo, acyl, amino, amido, aryl, arylalkyl, heteroaryl; R5 = H, halo, alkyl, alkenyl, alkynyl, acyl, amino, amido, aryl, arylalkyl, heteroaryl; R6 = H, alkyl, alkoxyalkyl; X = NR9 where R9 = H or alkyl; and Y = (CR7R8)n; n = 0-5], were prepared for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome, etc. (no data). Thus, Et 5-amino-6-chloroimidazo[1,2-a]pyridine-8-carboxylate (preparation given) was stirred 20 min. with carbonyldiimidazole; 1-(1-butyl-4-piperidinyl)methanamine and Et3N were added followed by stirring overnight to give 40% 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloroimidazo[1,2-a]pyridine-8-carboxamide.

IT 519147-74-1P 519147-75-2P 519147-78-5P

519147-80-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of imidazopyridines as 5-HT4 receptor modulators)


RN 519147-74-1 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro- (9CI) (CA INDEX NAME)


10667182



RN 519147-75-2 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 519147-78-5 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro-2-methyl- (9CI) (CA INDEX NAME)



10667182

RN 519147-80-9 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[(1-(3-methoxypropyl)-4-piperidinyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




IT 519148-29-9P 519148-30-2P 519148-31-3P
519148-32-4P 519148-33-5P 519148-34-6P
519148-36-8P 519148-37-9P 519148-40-4P
519148-41-5P 519148-42-6P 519148-43-7P
519148-45-9P 519148-46-0P 519148-48-2P
519148-50-6P 519148-51-7P 519148-52-8P
519148-53-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazopyridines as 5-HT4 receptor modulators)

RN 519148-29-9 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, N-[(1-butyl-4-piperidinyl)methyl]-6-chloro-5-(methylamino)- (9CI) (CA INDEX NAME)




RN 519148-30-2 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 6-chloro-N-[(1-(3-methoxypropyl)-4-piperidinyl)methyl]-5-(methylamino)- (9CI) (CA INDEX NAME)


10667182



RN 519148-31-3 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 519148-32-4 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-3-chloro-2-ethyl- (9CI) (CA INDEX NAME)



10667182


RN 519148-33-5 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[(1-(3-methoxypropyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 519148-34-6 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-2-ethyl-N-[(1-(3-methoxypropyl)-4-piperidinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 519148-36-8 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro-2-propyl-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 519148-02-8


CMF C₂₁ H₃₂ Cl N₅ O

10667182




CM 2

CRN 104-15-4
CMF C7 H8 O3 S




RN 519148-37-9 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 519148-40-4 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2-(1-methylethyl)-6-chloro- (9CI) (CA INDEX NAME)

10667182




RN 519148-41-5 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 519148-42-6 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro-2-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




10667182

RN 519148-43-7 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 519148-45-9 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2,6-dichloro- (9CI) (CA INDEX NAME)




RN 519148-46-0 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-2-chloro- (9CI) (CA INDEX NAME)

10667182




RN 519148-48-2 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-methyl-N-[(1-(2-methylpropyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 519148-50-6 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-2-methyl-N-[(1-(2-methylpropyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




10667182


RN 519148-51-7 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(3,3-dimethylbutyl)-4-piperidinyl]methyl]-2-ethyl- (9CI) (CA INDEX NAME)



RN 519148-52-8 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[[1-(2-methoxy-2-methylpropyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 519148-53-9 CAPLUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-N-[[1-(2-methoxy-2-methylpropyl)-4-piperidinyl]methyl]-2-methyl- (9CI) (CA INDEX NAME)




IT **519147-97-8P 519147-98-9P 519147-99-0P**
519148-02-8P 519148-09-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of imidazopyridines as 5-HT4 receptor modulators)

RN 519147-97-8 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro-2-ethyl- (9CI) (CA INDEX NAME)



RN 519147-98-9 CAPLUS


CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-6-chloro-2-ethyl-N-[(1-(3-methoxypropyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

10667182




RN 519147-99-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(5-amino-6-chloro-2-ethylimidazo[1,2-a]pyridin-8-yl)carbonyl]amino]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 519148-02-8 CAPLUS

CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro-2-propyl- (9CI) (CA INDEX NAME)



10667182

RN 519148-09-5 CAPIUS
CN Imidazo[1,2-a]pyridine-8-carboxamide, 5-amino-N-[(1-butyl-4-piperidinyl)methyl]-6-chloro-2-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT